Cure8 research brief
The study links a cellular signaling pathway that increases serotonin release from gut enterochromaffin cells to inflammation in a mouse model of ulcerative colitis. If confirmed, blocking TRPV4 could become a research direction for therapies that reduce serotonin-mediated gut inflammation.
Researchers studying IBD pathogenesis or drug targets, gastroenterology clinicians interested in mechanistic research, and translational scientists working on new therapies for UC.
This paper describes basic-science work (cell and mouse experiments) linking TRPV4-dependent calcium entry in enterochromaffin cells to acetylcholine-stimulated serotonin release and to a mouse model of ulcerative colitis.
The authors propose a mAChR/IP3/IP3R/TRPV4/5-HT pathway and show that pharmacologic TRPV4 inhibition lessened 5-HT release and disease severity in DSS-treated mice.
The findings suggest TRPV4 in enterochromaffin cells could be a potential target for future therapies aimed at reducing serotonin-driven inflammation in UC, but these are preclinical results from a single study and not evidence of safety or efficacy in people.
This is preclinical laboratory and mouse-model research (basic science). Results in cells and DSS mice do not directly translate to human clinical benefit; further validation, safety testing, and clinical trials would be required.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Natural Science Foundation of China, award No. 82570647; National Natural Science Foundation of China, award No. 82273115
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests a possible link between psoriasis, leaky gut, and Crohn’s disease—topics that could help explain why some people with psoriasis report more gut problems. People with psoriasis or IBD may find the...
The study identifies a new macrophage-driven immune pathway (VDAC1-mediated mtDNA release activating cGAS–STING) that contributes to ulcerative colitis in preclinical models and suggests a plant-derived compound (SEI)...
The study identifies a cellular mechanism by which arctigenin reduced inflammatory macrophage death and improved colitis in mice, suggesting a potential new target (macrophage FAO → GSDMD) for therapies or...
